https://socratec-pharma.de/presentations/neue-arzneimittel-strategien-zur-vermeidung-gefaehrlicher-interaktionen 2015-08-13T09:40:18+00:00 monthly 0.6 https://socratec-pharma.de/presentations/proof-of-concept-stellenwert-von-pd-studien-und-surrogatparametern 2015-08-13T09:40:19+00:00 monthly 0.6 https://socratec-pharma.de/presentations/therapeutische-optimierung-nicht-denkbar-ohne-klinische-rationale 2015-08-13T09:40:20+00:00 monthly 0.6 https://socratec-pharma.de/presentations/arzneimittel-fe-heute-wiederentdeckung-der-arzneiform 2015-08-13T09:40:21+00:00 monthly 0.6 https://socratec-pharma.de/presentations/designing-and-evaluating-babe-studies-in-the-21st-century 2015-08-13T09:40:22+00:00 monthly 0.6 https://socratec-pharma.de/presentations/anlage-und-durchfuehrung-von-bioverfuegbarkeitsuntersuchungen 2015-08-13T09:40:23+00:00 monthly 0.6 https://socratec-pharma.de/presentations/anlage-und-durchfuehrung-von-bioaequivalenzstudien 2015-08-13T09:40:24+00:00 monthly 0.6 https://socratec-pharma.de/presentations/charakterisierung-der-bioverfuegbarkeitbioaequivalenz-grundkonzept-und-studienansaetze 2015-08-13T09:40:25+00:00 monthly 0.6 https://socratec-pharma.de/presentations/nachweis-der-bioaequivalenz-wann-welche-studienkonzeption 2015-08-13T09:40:26+00:00 monthly 0.6 https://socratec-pharma.de/presentations/aktuelle-fragen-zur-bioaequivalenz 2015-08-13T09:40:27+00:00 monthly 0.6 https://socratec-pharma.de/presentations/innovative-galenik-die-voraussetzung-fuer-eine-optimierte-therapie-des-chronischen-schmerzes 2015-08-13T09:40:28+00:00 monthly 0.6 https://socratec-pharma.de/presentations/properties-of-special-populations 2015-08-13T09:40:29+00:00 monthly 0.6 https://socratec-pharma.de/presentations/magen-darm-therapeutika-warum-ist-die-arzneiform-so-bedeutsam 2015-08-13T09:40:30+00:00 monthly 0.6 https://socratec-pharma.de/presentations/babe--an-important-link-between-drug-quality-and-efficacysafety 2015-08-13T09:40:31+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioverfuegbarkeitbioaequivalenz-und-magen-darm-physiologie-wird-das-konzept-auf-den-kopf-gestellt 2015-08-13T09:40:32+00:00 monthly 0.6 https://socratec-pharma.de/presentations/new-perspectives-for-added-value-generics 2015-08-13T09:40:33+00:00 monthly 0.6 https://socratec-pharma.de/presentations/sicherheit-und-vertraeglichkeit-von-propiverin-bei-patienten-mit-nierenfunktionseinschraenkung 2015-08-13T09:40:34+00:00 monthly 0.6 https://socratec-pharma.de/presentations/arzneimittel-konflikt-zwischen-kosten-und-qualitaet 2015-08-13T09:40:35+00:00 monthly 0.6 https://socratec-pharma.de/presentations/retardformen-und-food-effects-von-dose-dumping-und-anderen-unerfreulichen-ueberraschungen 2015-08-13T09:40:36+00:00 monthly 0.6 https://socratec-pharma.de/presentations/retardarzneiformen-was-tun-bei-nicht-aequivalenz 2015-08-13T09:40:37+00:00 monthly 0.6 https://socratec-pharma.de/presentations/single-vs-multiple-dose-studien-standards-und-besonderheiten 2015-08-13T09:40:38+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioavailabilitybioequivalence-practise-and-issues 2015-08-13T09:40:39+00:00 monthly 0.6 https://socratec-pharma.de/presentations/fentanyl-pflaster--eine-therapeutische-bereicherung 2015-08-13T09:40:40+00:00 monthly 0.6 https://socratec-pharma.de/presentations/once-daily-nifedipine-products-are-they-really-interchangeable 2015-08-13T09:40:41+00:00 monthly 0.6 https://socratec-pharma.de/presentations/drug-interaction-studies-the-rational-selection-of-drug-interaction-studies 2015-08-13T09:40:42+00:00 monthly 0.6 https://socratec-pharma.de/presentations/biosimilars--qualitaet-und-sicherheit-einer-besonderen-arzneimittelgruppe 2015-08-13T09:40:43+00:00 monthly 0.6 https://socratec-pharma.de/presentations/neue-konzepte-fuer-die-optimierung-oraler-antidiabetika 2015-08-13T09:40:44+00:00 monthly 0.6 https://socratec-pharma.de/presentations/schlucken-oder-kleben--biopharmazeutische-antworten-auf-eine-therapierelevante-frage 2015-08-13T09:40:45+00:00 monthly 0.6 https://socratec-pharma.de/presentations/innovation-oder-scheininnovation-welche-rolle-spielt-die-arzneiform 2015-08-13T09:40:46+00:00 monthly 0.6 https://socratec-pharma.de/presentations/leitsubstanzen-in-der-arzneitherapie-konflikt-zwischen-wirtschaftlichkeit-und-innovationen 2015-08-13T09:40:47+00:00 monthly 0.6 https://socratec-pharma.de/presentations/modified-release-oxcarbazepine-challenges-and-successful-development 2015-08-13T09:40:48+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioavailability-and-bioequivalence-studies-for-modified-release-products 2015-08-13T09:40:49+00:00 monthly 0.6 https://socratec-pharma.de/presentations/hightech-in-der-schmerztherapie-therapeutische-optimierung-durch-osmotisch-gesteuerte-retardform 2015-08-13T09:40:50+00:00 monthly 0.6 https://socratec-pharma.de/presentations/gastro-intestinal-transit-of-solid-oral-dosage-forms-imaging-studies-using-magnetic-marker-monitoring-technique 2015-08-13T09:40:51+00:00 monthly 0.6 https://socratec-pharma.de/presentations/optimierte-arzneiformen-zur-verbesserung-der-pharmakotherapie-beim-alten-menschen 2015-08-13T09:40:52+00:00 monthly 0.6 https://socratec-pharma.de/presentations/life-cycle-management-new-chances-for-old-drugs 2015-08-13T09:40:53+00:00 monthly 0.6 https://socratec-pharma.de/presentations/the-need-for-and-approaches-to-a-european-healthy-volunteer-database 2016-11-22T10:43:05+00:00 monthly 0.6 https://socratec-pharma.de/presentations/therapeutische-optimierung-durch-galenische-modifizierung 2015-08-13T09:40:55+00:00 monthly 0.6 https://socratec-pharma.de/presentations/optimising-gi-absorption-of-modified-release-products 2015-08-13T09:40:56+00:00 monthly 0.6 https://socratec-pharma.de/presentations/assessment-of-intestinal-and-hepatic-first-pass-necessity-to-measure-metabolites 2015-08-13T09:40:57+00:00 monthly 0.6 https://socratec-pharma.de/presentations/site-dependent-drug-absorption-and-impact-on-babe-assessment 2016-11-22T10:40:37+00:00 monthly 0.6 https://socratec-pharma.de/presentations/iontophorese-und-postoperative-schmerztherapie 2015-08-13T09:40:59+00:00 monthly 0.6 https://socratec-pharma.de/presentations/therapie-chronischer-schmerzzustaende-kriterien-fuer-optimale-opiodarzneimittel 2015-08-13T09:41:00+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pharmakologische-bewertung-oraler-antidiabetika 2015-08-13T09:41:01+00:00 monthly 0.6 https://socratec-pharma.de/presentations/antihypertensive-therapie-warum-die-arztneimittelqualitaet-hier-besonders-wichtig-ist 2015-08-13T09:41:02+00:00 monthly 0.6 https://socratec-pharma.de/presentations/successfully-performing-bioavailabilitybioequivalence-studies-for-modified-release-products 2015-08-13T09:41:03+00:00 monthly 0.6 https://socratec-pharma.de/presentations/new-therapeutic-entities-novel-biopharmaceutical-concepts-for-improved-clinical-efficacy 2015-08-13T09:41:04+00:00 monthly 0.6 https://socratec-pharma.de/presentations/food-effect-studies-towards-science-driven-regulations 2015-08-13T09:41:05+00:00 monthly 0.6 https://socratec-pharma.de/presentations/revision-of-the-cpmp-note-for-guidance-on-babe-impact-on-the-development-of-generic-medicinal-products 2015-08-13T09:41:06+00:00 monthly 0.6 https://socratec-pharma.de/presentations/babe-studies-with-modified-release-products--a-european-perspective 2015-08-13T09:41:07+00:00 monthly 0.6 https://socratec-pharma.de/presentations/austauschbarkeit-von-antiepileptika--pro-und-contra 2015-08-13T09:41:08+00:00 monthly 0.6 https://socratec-pharma.de/presentations/impact-of-product-quality-on-the-treatment-with-alpha-lipoic-acid 2015-08-13T09:41:09+00:00 monthly 0.6 https://socratec-pharma.de/presentations/physiologische-und-pharmakologische-grundlagen-inkretinbasierter-therapieansaetze 2015-08-13T09:41:10+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioverfuegbarkeit-und-rabattvertraege--ein-problematisches-wechselspiel 2015-08-13T09:41:11+00:00 monthly 0.6 https://socratec-pharma.de/presentations/development-of-super-generic-new-chances-for-old-drugs 2015-08-13T09:41:12+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bedeutung-gleichmaessiger-plasmaprofile-in-der-schmerztherapie 2015-08-13T09:41:13+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bcs-based-biowaiver-extension-to-class-iii-drugs 2015-08-13T09:41:14+00:00 monthly 0.6 https://socratec-pharma.de/presentations/orodispersible-tablets-necessity-to-investigate-fed-and-fasted-intake 2015-08-13T09:41:15+00:00 monthly 0.6 https://socratec-pharma.de/presentations/revision-of-cpmp-note-for-guidance-on-babe-regulatory-and-scientific-rationale 2015-08-13T09:41:16+00:00 monthly 0.6 https://socratec-pharma.de/presentations/charakterisierung-der-in-vitro-freisetzung-fester-oraler-darreichungsformen 2015-08-13T09:41:17+00:00 monthly 0.6 https://socratec-pharma.de/presentations/therapeutische-optimierung-durch-innovative-arzneiformen 2015-08-13T09:41:18+00:00 monthly 0.6 https://socratec-pharma.de/presentations/qualitaet-und-innovation-als-mehrwertsteuer--chancen-fuer-added-value-generics 2015-08-13T09:41:19+00:00 monthly 0.6 https://socratec-pharma.de/presentations/schlafstoerung-bei-der-behandlung-chronischer-schmerzzustaende--besserung-durch-optimale-galenik 2015-08-13T09:41:20+00:00 monthly 0.6 https://socratec-pharma.de/presentations/biosimilars--how-similar-is-similar 2015-08-13T09:41:21+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioequivalence-regulations--bar-or-driving-force-for-progress-in-science-and-technology 2015-08-13T09:41:22+00:00 monthly 0.6 https://socratec-pharma.de/presentations/highly-variable-drugs-how-to-solve-significant-problems-assessing-bioequivalence 2015-08-13T09:41:23+00:00 monthly 0.6 https://socratec-pharma.de/presentations/aut-idem-substitution-sind-analgetika-zur-therapie-chronischer-schmerzen-einfach-austauschbar 2015-08-13T09:41:24+00:00 monthly 0.6 https://socratec-pharma.de/presentations/seminar-bioavailabilitybioequivalence-and-in-vitro-dissolution 2015-08-13T09:41:25+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioequivalence-regulations-survey-of-international-requirements 2015-08-13T09:41:26+00:00 monthly 0.6 https://socratec-pharma.de/presentations/survey-of-international-bioequivalence-requirements 2015-08-13T09:41:27+00:00 monthly 0.6 https://socratec-pharma.de/presentations/babe-studies-with-mr-products-a-european-perspective 2015-08-13T09:41:28+00:00 monthly 0.6 https://socratec-pharma.de/presentations/phase-i-studien-wie-werden-die-anforderungen-und-schnittstellen-effizient-vereinbart 2015-08-13T09:41:29+00:00 monthly 0.6 https://socratec-pharma.de/presentations/vom-konzept-zur-praxis--klinische-pruefung-unter-nutzung-von-surrogatparametern 2015-08-13T09:41:30+00:00 monthly 0.6 https://socratec-pharma.de/presentations/therapeutische-optimierung-durch-innovative-arzneiformen 2015-08-13T09:41:31+00:00 monthly 0.6 https://socratec-pharma.de/presentations/use-of-bcs-in-product-development-background--concept--perspective 2015-08-13T09:41:32+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bcs-based-biowaivers 2015-08-13T09:41:33+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioavailability-bioequivalence-development-of-international-regualtory-requirements 2015-08-13T09:41:34+00:00 monthly 0.6 https://socratec-pharma.de/presentations/be-of-modified-release-products-difficult-eytrapolation-from-in-vitro 2015-08-13T09:41:35+00:00 monthly 0.6 https://socratec-pharma.de/presentations/the-class-war-the-problem-of-combining-bcs-class-i-and-iii-in-biowaivers 2015-08-13T09:41:36+00:00 monthly 0.6 https://socratec-pharma.de/presentations/drugs-mainly-taken-by-the-elderly-be-testing-in-the-target-population 2015-08-13T09:41:37+00:00 monthly 0.6 https://socratec-pharma.de/presentations/food-effect-studies-towards-science-driven-regulations 2015-08-13T09:41:38+00:00 monthly 0.6 https://socratec-pharma.de/presentations/different-salts-of-a-pro-drug-more-restrictive-be-requirements 2015-08-13T09:41:39+00:00 monthly 0.6 https://socratec-pharma.de/presentations/before-or-after-a-meal-impact-of-administration-conditions-on-clinical-efficacy 2015-08-13T09:41:40+00:00 monthly 0.6 https://socratec-pharma.de/presentations/babe--important-link-between-drug-quality-and-efficacysafety 2015-08-13T09:41:41+00:00 monthly 0.6 https://socratec-pharma.de/presentations/modern-strategies-for-the-development-of-gerneric-drugs-locally-acting--locally-applied-drug-products-a-playing-field-for-human-pharmacologists 2015-08-13T09:41:42+00:00 monthly 0.6 https://socratec-pharma.de/presentations/modern-strategies-for-the-development-of-gerneric-drugs-highly-variable-drugs-mechanisms-for-high-variability-and-resolutions-to-overcome-the-differences 2015-08-13T09:41:43+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pharmazeutische-bedenken-und-rabattvertraege-aut-idem-lichte-der-guten-substitutionspraxis 2015-08-13T09:41:44+00:00 monthly 0.6 https://socratec-pharma.de/presentations/lueckenlose-schmerzkontrolle-in-der-opiat-therapie-behandlungslonzept-und-erwartungen-an-der-arzneiform 2015-08-13T09:41:45+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pharmako-therapeutische-schmerzkontrolle-besonderheiten-unterschiedlicher-applikationswege 2015-08-13T09:41:46+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioequivalence-regulations-for-modified-release-products-necessity-of-single-dose-fasted-food-effect--multiple-dose-studies 2015-08-13T09:41:47+00:00 monthly 0.6 https://socratec-pharma.de/presentations/emas-bioanalytical-guidance 2015-08-13T09:41:48+00:00 monthly 0.6 https://socratec-pharma.de/presentations/major-differences-beetwen-ema-fda-and-who-guidances-in-be-and-bcs 2015-08-13T09:41:49+00:00 monthly 0.6 https://socratec-pharma.de/presentations/drug-delivery-technologies-to-optimize-the-clinical-application-of-drugs 2016-11-22T10:38:37+00:00 monthly 0.6 https://socratec-pharma.de/presentations/selection-of-reference-product-in-bioequivalence-studies-for-submission-to-multiple-jurisdictions 2015-08-13T09:41:51+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pruefpraeparate-auswahl-und-charakterisierung-qualitaetsanforderungen-bevorzugte-wirkstaerke-bracketing-etc 2015-08-13T09:41:52+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioaequivalenzstudien-mit-speziellen-arzneimitteln-fdc-odt-etc 2016-11-22T11:38:41+00:00 monthly 0.6 https://socratec-pharma.de/presentations/food-effect-studies-influence-of-population-characteristics-and-standardisation-of-clinical-procresses 2015-08-13T09:41:54+00:00 monthly 0.6 https://socratec-pharma.de/presentations/example-for-an-early-drug-device-development-plan 2015-08-13T09:41:55+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioequivalence-andor-therapeutic-equivalence-for-generics--not-by-choice-but-must 2015-08-13T09:41:56+00:00 monthly 0.6 https://socratec-pharma.de/presentations/clinical-trials-for-line-extension-added-value-generics-and-novel-drug-delivery-systems 2015-08-13T09:41:57+00:00 monthly 0.6 https://socratec-pharma.de/presentations/kostensenkung-durch-generische-substitution-und-rabattvertraege-muss-der-patient-die-zeche-zahlen 2015-08-13T09:41:58+00:00 monthly 0.6 https://socratec-pharma.de/presentations/enhanced-pdclinical-outcome-through-optimizing-drug-delivery 2015-08-13T09:41:59+00:00 monthly 0.6 https://socratec-pharma.de/presentations/dpp-4-inhibitoren-ein-vergleich-aus-pharmakologischer-sicht 2015-08-13T09:42:00+00:00 monthly 0.6 https://socratec-pharma.de/presentations/be-studies-in-patient-populations--new-challenges-and-future-trends 2015-08-13T09:42:01+00:00 monthly 0.6 https://socratec-pharma.de/presentations/european-perspective-for-fixed-dose-combinations 2015-08-13T09:42:02+00:00 monthly 0.6 https://socratec-pharma.de/presentations/biopharmazie-einfluss-der-arzneimittelform-auf-die-arzneimittelwirkung 2015-08-13T09:42:03+00:00 monthly 0.6 https://socratec-pharma.de/presentations/einfluss-der-physiologie-des-magen-darm-traktes-auf-die-resorption-von-arzneimitteln 2015-08-13T09:42:04+00:00 monthly 0.6 https://socratec-pharma.de/presentations/medikamentoese-schmerztherapie-warum-die-galenik-so-entscheidend-ist 2015-08-13T09:42:05+00:00 monthly 0.6 https://socratec-pharma.de/presentations/kostensenkung-durch-generische-substitution-und-rabattvertraege-muss-der-patient-die-zeche-zahlen 2015-08-13T09:42:06+00:00 monthly 0.6 https://socratec-pharma.de/presentations/chmp-guideline-on-bioanalytical-method-validation 2015-08-13T09:42:07+00:00 monthly 0.6 https://socratec-pharma.de/presentations/draft-reflection-paper-on-guidance-for-laboratories-analysing-or-evaluating-clinical-trial-samples 2015-08-13T09:42:08+00:00 monthly 0.6 https://socratec-pharma.de/presentations/revised-european-be-guideline-major-changes-new-challenges 2015-08-13T09:42:09+00:00 monthly 0.6 https://socratec-pharma.de/presentations/biopharmazeutische-konzepte-koennen-medikamentoese-therapie-optimieren 2015-08-13T09:42:10+00:00 monthly 0.6 https://socratec-pharma.de/presentations/anlage-und-durchfuehrung-von-bioverfuegbarkeits--und-bioaequivalenzstudien 2015-08-13T09:42:11+00:00 monthly 0.6 https://socratec-pharma.de/presentations/verhalten-von-retardarzneimitteln-im-magen-darm-trakt-bedeutung--interpretation-von-food-effects 2015-08-13T09:42:12+00:00 monthly 0.6 https://socratec-pharma.de/presentations/generische-substitution-ist-ein-austausch-mit-therapeutischen-risiken-verbunden 2015-08-13T09:42:13+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pharmacokinetics-meets-biopharmaceutics-rationale-for-chrono-adjusted-pharmacotherapy 2015-08-13T09:42:14+00:00 monthly 0.6 https://socratec-pharma.de/presentations/generating-meaningful-clinical-information-impact-ofon-early-formulation-development 2015-08-13T09:42:15+00:00 monthly 0.6 https://socratec-pharma.de/presentations/be-and-adme-studies-in-oncological-patient-populations 2015-08-13T09:42:16+00:00 monthly 0.6 https://socratec-pharma.de/presentations/opioid-retardarzneimittel-warum-ist-die-galenik-so-bedeutsam 2015-08-13T09:42:17+00:00 monthly 0.6 https://socratec-pharma.de/presentations/chmp-guideline-on-bioanalytical-method-validation 2015-08-13T09:42:18+00:00 monthly 0.6 https://socratec-pharma.de/presentations/liposomal-iv-preparations-rationale-for-development--characterization 2015-08-13T09:42:19+00:00 monthly 0.6 https://socratec-pharma.de/presentations/phase-i-studies-with-newly-developed-liposomal-formulations-safety-and-efficacy-issues 2015-08-13T09:42:20+00:00 monthly 0.6 https://socratec-pharma.de/presentations/babe-in-paediatric-population--what-may-be-extrapolated-from-findings-in-adults 2015-08-13T09:42:21+00:00 monthly 0.6 https://socratec-pharma.de/presentations/biosimilars-concepts-for-therapeutic-antibodies 2015-08-13T09:42:22+00:00 monthly 0.6 https://socratec-pharma.de/presentations/how-to-substitute-efficacysafety-studies-by-pd-analysis-in-locally-appliedlocally-acting-drugs 2015-08-13T09:42:23+00:00 monthly 0.6 https://socratec-pharma.de/presentations/implants-and-vaginally-administered-devices 2015-08-13T09:42:24+00:00 monthly 0.6 https://socratec-pharma.de/presentations/validation-of-pharmacodynamic-methods-and-endpoints 2015-08-13T09:42:25+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pharmacokinetic-and-bioanalytical-issues-in-patient-studies 2015-08-13T09:42:26+00:00 monthly 0.6 https://socratec-pharma.de/presentations/protocol-development-definition-of-inex-criteria-and-clinical-conduct-of-babe-studies-in-patients 2016-11-22T10:37:47+00:00 monthly 0.6 https://socratec-pharma.de/presentations/development-of-formulations-with-added-value 2015-08-13T09:42:28+00:00 monthly 0.6 https://socratec-pharma.de/presentations/revised-european-guideline-on-pharmacokinetic-and-clinical-evaluation-of-modified-release-dosage-forms 2015-08-13T09:42:29+00:00 monthly 0.6 https://socratec-pharma.de/presentations/wann-ist-der-gesunde-proband-gesund-genug-fuer-die-klinische-pruefung 2015-08-13T09:42:30+00:00 monthly 0.6 https://socratec-pharma.de/presentations/the-basics-of-human-pharmacology-trial-medication 2015-08-13T09:42:31+00:00 monthly 0.6 https://socratec-pharma.de/presentations/gcp--glp--focus-on-method-validation-bioanalytics-sample-collection-sample-preparation-quality-assurance-procedures 2015-08-13T09:42:32+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pkpd-trials-in-drug-device-combinations-inhaled-glucocorticoids-as-example-for-complex-early-clinical-development-plans 2015-08-13T09:42:33+00:00 monthly 0.6 https://socratec-pharma.de/presentations/how-relevant-are-drug-food-interactions 2015-08-13T09:42:34+00:00 monthly 0.6 https://socratec-pharma.de/presentations/how-to-increase-drugability-by-use-of-specific-formulations--locally-acting-locally-applied 2015-08-13T09:42:35+00:00 monthly 0.6 https://socratec-pharma.de/presentations/investigating-individual-plasma-profiles-conclusion-on-comparability-of-product-performance-and-site-of-drug-deliveryabsorption-from-the-gi-tract 2015-08-13T09:42:36+00:00 monthly 0.6 https://socratec-pharma.de/presentations/example-sulfasalazine--combination-of-bioequivalence--localisation-study 2015-08-13T09:42:37+00:00 monthly 0.6 https://socratec-pharma.de/presentations/ema-consideration-for-locally-acting-drugs-in-the-gi-tract 2015-08-13T09:42:38+00:00 monthly 0.6 https://socratec-pharma.de/presentations/key-note-bedeutung-der-clinical-trial-regulation-fuer-die-humanpharmakologische-forschung-in-deutschland 2015-08-13T09:42:39+00:00 monthly 0.6 https://socratec-pharma.de/presentations/trial-medication-drug-substance-product-route-of-administration-formulations-drug-food-interaction-specific-aspects-of-preparation-administration-storage-in-phase-i-drug-accountability-test-refer 2018-09-02T21:27:54+00:00 monthly 0.6 https://socratec-pharma.de/presentations/oncological-drugs-early-development-from-pre-clinics-to-phase-ii 2015-08-13T09:42:41+00:00 monthly 0.6 https://socratec-pharma.de/presentations/aut-idem--wie-gleich-sind-generika 2015-08-13T09:42:42+00:00 monthly 0.6 https://socratec-pharma.de/presentations/introductory-session--why-a-global-bioequivalence-harmonisation-initiative-now 2015-08-13T09:42:43+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bcs-based-biowaiver-for-class-iii-drugs 2015-08-13T09:42:44+00:00 monthly 0.6 https://socratec-pharma.de/presentations/reference-product-clinical-rationale-of-smpc-recommendations-for-administration 2015-08-13T09:42:45+00:00 monthly 0.6 https://socratec-pharma.de/presentations/the-basics-of-human-pharmacology-gcp--glp--focus-on-method-validation-bioanalytics-sample-collection-sample-preparation-quality-assurance-procedures 2015-08-13T09:42:46+00:00 monthly 0.6 https://socratec-pharma.de/presentations/bioequivalence-trials-design-development-and-realization-practical-examples-specific-aspects-besides-the-classical-standard-design 2015-08-13T09:42:47+00:00 monthly 0.6 https://socratec-pharma.de/presentations/gcp-and-gmp-inspections-in-phase-i-what-can-be-learned 2015-08-13T09:42:48+00:00 monthly 0.6 https://socratec-pharma.de/presentations/mr-products-developed-as-line-extension-of-already-approved-ir-formulations 2015-08-13T09:42:49+00:00 monthly 0.6 https://socratec-pharma.de/presentations/pk-characteristics-and-statistical-evaluation-of-be-studies-how-to-handle-the-newly-introduced-endpoints-and-how-to-apply-adaptive-designs 2015-08-13T09:42:50+00:00 monthly 0.6 https://socratec-pharma.de/presentations/food-effect-studies-with-mr-products--when-and-how 2015-08-13T09:42:51+00:00 monthly 0.6 https://socratec-pharma.de/presentations/mr-dosage-forms-with-special-release-characteristics 2015-08-13T09:42:52+00:00 monthly 0.6 https://socratec-pharma.de/presentations/patch-development-with-new-drugs-versus-generic-development--principles-and-methods 2015-08-13T09:42:53+00:00 monthly 0.6 https://socratec-pharma.de/presentations/how-to-realise-patch-adhesion-studies 2015-08-13T09:42:54+00:00 monthly 0.6 https://socratec-pharma.de/presentations/compounds-with-pre-systemic-site-of-action-is-the-be-concept-applicable 2016-08-15T06:54:24+00:00 monthly 0.6 https://socratec-pharma.de/presentations/be-assessment-in-patient-population-highly-variable-products-with-critical-toxicological-profile 2016-08-15T06:56:55+00:00 monthly 0.6 https://socratec-pharma.de/presentations/quality-management-systems-in-early-phase-clinical-pharmacology-units-and-differences-between-qms-at-sponsors-cros-and-investigators-site 2016-08-15T10:30:53+00:00 monthly 0.6 https://socratec-pharma.de/presentations/relevance-of-gclp-and-validation-procedures-in-the-clinical-setting-of-early-phase-trials-in-healthy-subjects-and-patients 2016-08-15T07:19:25+00:00 monthly 0.6 https://socratec-pharma.de/presentations/inspection-safe-chain-of-custody-a-complex-interplay-of-quality-management-system-qualification-study-protocol-source-data-sheets-and-crf 2016-08-15T10:35:41+00:00 monthly 0.6 https://socratec-pharma.de/presentations/drug-drug-interaction-and-bioavailability-trials-in-oncological-patient-populations 2017-03-14T07:55:53+00:00 monthly 0.6 https://socratec-pharma.de/presentations/regulatory-landscape-in-europein-view-of-implementing-the-new-regulation-for-harmonised-submission 2019-11-01T06:13:14+00:00 monthly 0.6 https://socratec-pharma.de/presentations/justification-to-deviate-from-high-fat-meals-in-bioequivalence-trials-with-immediate-release-products 2019-12-08T07:38:31+00:00 monthly 0.6 https://socratec-pharma.de/presentations/systemic-pharmacokinetic-study-design-considerations-for-orally-inhaled-drug-products-oidps 2019-11-01T06:12:55+00:00 monthly 0.6 https://socratec-pharma.de/presentations/global-harmonisation-of-bioequivalence-requirements-vision-perspective-or-illusion 2019-12-08T07:43:55+00:00 monthly 0.6 https://socratec-pharma.de/presentations/arzneimittelentwicklung-und-forschung-nach-der-zulassung 2022-08-17T14:13:22+00:00 monthly 0.6 https://socratec-pharma.de/presentations/einfuehrung-und-ueberblick-ueber-die-pharmakologie-im-rahmen-der-wqs 2022-08-17T14:15:00+00:00 monthly 0.6 https://socratec-pharma.de/presentations/introduction-to-session-3-equivalence-assessment-of-topical-products-product-dependent-approaches-why-the-site-of-action-matters-also-for-topicals 2022-08-18T07:05:02+00:00 monthly 0.6 https://socratec-pharma.de/presentations/human-pk-studies-iii-interplay-between-biopharmaceutics-and-absorption 2022-08-18T06:44:54+00:00 monthly 0.6 https://socratec-pharma.de/presentations/introducion-to-session-2-be-considerations-for-modified-release-mr-drug-products-single-dose-vs-multiple-dose-studies-and-strength-waiver-summary-of-preceding-gbhi-discussions-on-mr-drug-products 2024-02-22T13:40:10+00:00 monthly 0.6 https://socratec-pharma.de/presentations/systemic-pharmacokinetic-be-studies-with-and-without-blocked-gi-absorption-to-predict-regional-lung-exposure 2024-02-22T13:43:32+00:00 monthly 0.6 https://socratec-pharma.de/presentations/closing-remarks-of-scientific-session-on-be-study-consideration-for-orally-inhaled-drug-products-oips 2024-02-22T13:46:14+00:00 monthly 0.6 https://socratec-pharma.de/presentations/regulatory-aspects-of-virtual-clinical-trials 2024-02-22T13:51:23+00:00 monthly 0.6 https://socratec-pharma.de/presentations/summary-about-gbhi-discussion-on-the-be-demonstration-of-additional-strength-for-solid-oral-mr-products 2024-02-22T13:54:46+00:00 monthly 0.6